<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1304233540
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Recarbrio
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IMIPENEM,CILASTATIN,RELEBACTAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500,500,250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        15509.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SHARP AND DOHME LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SHARP AND DOHME LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Merck Sharp & Dohme B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DH56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Recarbrio is an antibiotic. It contains the active substances imipenem, cilastatin, and relebactam. Recarbrio is used in adults to treat:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain bacterial infections of the lungs (pneumonia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections of the blood associated with the infections of the lung mentioned above</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections caused by bacteria that other antibiotics may not be able to kill Recarbrio is used in patients 18 years or older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not be given Recarbrio if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to imipenem, cilastatin, relebactam or any of the other ingredients of this medicine (listed in section 6)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to carbapenem antibiotics</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you ever had a severe allergic reaction to penicillin antibiotics or cephalosporin antibiotics</p><p>&nbsp;</p><p>You should not be given Recarbrio if any of the above apply to you. If you are not sure, talk to your doctor or nurse before being given Recarbrio.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or nurse before being given Recarbrio if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to any medicines - especially antibiotics</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had convulsions (seizures or fits)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had confusion or muscle twitches with a medicine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking a medicine containing valproic acid</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had diarrhoea while taking antibiotics in the past</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have kidney problems &ndash; your doctor may lower your dose</p><p>Tell your doctor right away if you have an allergic reaction, convulsions (seizures or fits), diarrhoea, or develop kidney problems while receiving Recarbrio (see section 3).</p><p>&nbsp;</p><p>Children and adolescents</p><p>Recarbrio should not be used in children or adolescents who are under 18 years of age. This is because it is not known if the medicine is safe to use in these patients.</p><p>&nbsp;</p><p>Other medicines and Recarbrio</p><p>Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Tell your doctor about all the medicines you take, especially if you take:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that contain ganciclovir, used for treating some viral infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that contain valproic acid or divalproex sodium, usually used for treating epilepsy, bipolar disorder, or migraine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to control blood clotting, such as warfarin</p><p>&nbsp;</p><p>Pregnancy and breastfeeding</p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before being given this medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Recarbrio may make you feel dizzy, shaky, or cause convulsions or seizures. This may affect your ability to drive or use machines.</p><p>&nbsp;</p><p>Recarbrio contains sodium</p><p>This medicine contains approximately 37.5 mg of sodium (main component of cooking/ table salt) in each vial. This is equivalent to about 2 % of the adult recommended maximum amount of sodium you should take daily, and needs to be taken into account if you are on a low-salt diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The usual dose is one vial (containing 500 mg imipenem, 500 mg cilastatin, and 250 mg relebactam) every 6 hours. If you have kidney problems, your doctor may lower your dose.</p><p>&nbsp;</p><p>It is given as a drip directly into a vein (&lsquo;intravenous infusion&rsquo;). The infusion will last 30 minutes.</p><p>&nbsp;</p><p>The course of treatment usually lasts from 5 up to 14 days, depending on the type of infection you have and how you respond to treatment.</p><p>&nbsp;</p><p>If you are given more Recarbrio than you should</p><p>Recarbrio will be given to you by a doctor or a nurse, so it is unlikely you will be given the wrong dose. If you think you have been given too much Recarbrio, tell your doctor or nurse right away.</p><p>&nbsp;</p><p>If you miss a dose of Recarbrio</p><p>Tell your doctor or nurse right away if you think you were not given your dose of Recarbrio. If you have any further questions on the use of this medicine, ask your doctor or nurse</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Serious side effects</p><p>Tell your doctor right away if you notice any of the following serious side effects - the medicine must be stopped:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions &ndash; the signs may include hives, swelling of the face, lips, tongue or throat, difficulty in breathing or swallowing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions (e.g., severe rash, skin peeling or blistering)</p><p>&nbsp;</p><p>Other side effects</p><p><strong>Common</strong>: (may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea, being sick (vomiting), diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood test results that may show changes in the liver</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood test results that may show an increase in the number of some types of blood cells called &lsquo;eosinophils&rsquo;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood test results that may show an increase in some white blood cells</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation and pain caused by a blood clot in the vein</p><p>&nbsp;</p><p><strong>Uncommon</strong>: (may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin itchiness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsions (fits) and nervous system problems like tremor</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seeing, hearing or feeling something that is not there (hallucinations)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, sleepiness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood test results that may show changes in the kidney</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood test results that may show a decrease in the number of red blood cells, white blood cells, and blood cells called platelets</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood test results that may show an increase in the number of some blood cells called platelets</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal kidney, liver, and blood function detected by blood tests</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or redness or formation of a lump where the medicine was injected</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood test (called a Coombs test) results showing antibodies that can cause anaemia by destroying red blood cells</p><p>&nbsp;</p><p><strong>Rare</strong>: (may affect up to 1 in 1,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infection (candidiasis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in taste</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disease of the brain, tingling sensation (pins and needles), localised tremor</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hearing loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; staining of the teeth and/or tongue</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the colon with severe diarrhoea (colitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of white blood cells which may make it difficult for your body to fight infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability of the kidney to perform normal function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in the amount of urine, changes in urine color</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful rash with flu-like symptoms</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness and scaling of the skin</p><p>&nbsp;</p><p><strong>Very rare</strong>: (may affect up to 1 in 10,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of stomach or intestine (gastro-enteritis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia due to destruction of red blood cells, leading to symptoms like tiredness, pale skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening of a rare disease associated with muscle weakness (aggravation of myasthenia gravis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a spinning sensation (vertigo)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears (tinnitus)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heartbeat, the heart beating forcefully or rapidly</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest discomfort, difficulty breathing, abnormally fast and superficial breathing, pain in the upper spine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the throat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing, bluish discoloration of the face and lips, changes in skin texture, excessive sweating</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the production of saliva</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of intestine with bloody diarrhoea (haemorrhagic colitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heartburn</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red swollen tongue, overgrowth of the normal projections on the tongue giving it a hairy appearance</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe loss of liver function due to inflammation (fulminant hepatitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in several joints</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching of the vulva in women</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness, lack of energy</p><p>&nbsp;</p><p><strong>Not known</strong>: (frequency cannot be estimated from the available data)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal movements</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice (yellowing of your skin and eyes)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests showing an increase in a substance called lactic dehydrogenase (LDH) which may be a sign of tissue damage</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via National Pharmacovigilance and Drug Safety Centre (NPC), SFDA. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>Store below 30˚C.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the container.</p><p>&nbsp;</p><p>Keep this medicine in the outer carton to protect from light.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Recarbrio contains</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are imipenem, cilastatin, and relebactam. Each vial contains 500 mg imipenem, 500 mg cilastatin, and 250 mg relebactam.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient is sodium hydrogen carbonate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
What Recarbrio looks like and contents of the pack
Recarbrio is a white to light yellow powder supplied for solution for infusion in glass vials. Pack size is 25 vials.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></p><p>Merck Sharp &amp; Dohme B.V. Waarderweg 39</p><p>2031 BN Haarlem The Netherlands</p><p><strong>Manufacturer</strong></p><p>Merck Sharp &amp; Dohme LLC<br />2778 South East Side Highway<br />Elkton, Virginia 22827, USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                {Nov 2020}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ريكاربريو هو مُضاد حيوي يحتوي على المواد الفعّالة التالية: إيميبينيم وسيلاستاتين وريلبَكتام.</p><p dir="RTL">يُستخدم ريكاربيو لدى البالغين في علاج الحالات التالية:</p><p dir="RTL">&bull; بعض أنواع العدوى البكتيرية التي تصيب الرئتين (الالتهاب الرئوي)</p><p dir="RTL">&bull; التهابات الدم المصاحبة لالتهابات الرئة المذكورة أعلاه</p><p dir="RTL">&bull; الالتهابات التي تسببها البكتيريا التي قد لا تتمكن المضادات الحيوية الأخرى من القضاء عليها.</p><p dir="RTL">ريكاربريو يستخدم لدى المرضى الذين تبلغ أعمارهم 18 سنة أو أكثر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ينبغي ألا تتلقى ريكاربريو إذا كان:</strong></p><p dir="RTL">&bull; لديك حساسية نحو إيميبينيم، سيلاستاتين، ريلبَكتام أو نحو أي من المكونات الأخرى لهذا الدواء (المدرجة في الفقرة 6)</p><p dir="RTL">&bull; لديك حساسية نحو المضادات الحيوية من مجموعة كاربابينيم</p><p dir="RTL">&bull; عانيت من قبل من رد فعل تحسسي شديد تجاه المضادات الحيوية من مجموعة البِنسلين أو المضادات الحيوية من مجموعة السيفالوسبورين</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي أن تتلقى ريكاربريو إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا، تحدث إلى طبيبك أو ممرضك قبل أن يتم إعطاؤك ريكاربريو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو ممرضك قبل إعطائك ريكاربريو إذا:</p><p dir="RTL">&bull; كان لديك حساسية نحو أي أدوية - وخاصة المضادات الحيوية</p><p dir="RTL">&bull; عانيت من قبل من تشنجات (نوبات أو صرع)</p><p dir="RTL">&bull; عانيت في أي وقت مضى من الارتباك أو التشنجات العضلية أثناء تناول أي دواء.</p><p dir="RTL">&bull; كنت تتناول دواء يحتوي على حمض الفالبرويك</p><p dir="RTL">&bull; أُصبت بالإسهال أثناء تناول المضادات الحيوية في الماضي</p><p dir="RTL">&bull; كان لديك مشاكل في الكلى - قد يقوم طبيبك بخفض جرعتك</p><p dir="RTL">اخبر طبيبك على الفور إذا تعرضت لرد فعل تحسسي أو تشنجات (نوبات أو صرع) أو إسهال أو مشاكل في الكلى أثناء تلقيك ريكاربريو (انظر الفقرة 3).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينبغي استخدام ريكاربريو لدى الأطفال أو المراهقين الذين تقل أعمارهم عن 18 عامًا، وذلك لأنه من غير المعروف ما إذا كان الدواء آمنًا للاستخدام في هذه الفئة العمرية من المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وريكاربريو</strong></p><p dir="RTL">أخبر طبيبك أو ممرضك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك عن جميع الأدوية التي تتناولها، خاصة إذا كنت تتناول:</p><p dir="RTL">&bull; الأدوية التي تحتوي على جَنسيكلوفير، والتي تُستخدم لعلاج بعض الالتهابات الفيروسية</p><p dir="RTL">&bull; الأدوية التي تحتوي على حمض الفالبرويك أو صوديوم ديفالبركس، والتي تُستخدم عادة في علاج الصرع أو الاضطراب ثنائي القطب أو الصداع النصفي</p><p dir="RTL">&bull; الأدوية التي تُستخدم للتحكم في تخثر الدم مثل الوارفارين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا ، تعتقدين أنك حامل أو تخططين لإنجاب طفل، استشيري طبيبك قبل إعطائك هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قد يجعلك ريكاربريو تشعر بالدوار أو الاهتزاز أو قد يسبب تشنجات أو نوبات. وبالتالي قد يؤثر ذلك على قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي ريكاربريو على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على ما يقرب من 37,5 مجم من الصوديوم (المكوّن الرئيسي لملح الطبخ / ملح الطعام) في كل فيال &quot;قارورة&quot;. وهذا يعادل حوالي 2٪ من الحد الأقصى الموصى به للبالغين من الصوديوم الذي يجب أن تتناوله يوميًّا، ويجب أن يؤخذ هذا في الاعتبار إذا كنت تتبع نظامًا غذائيًّا قليل الملح.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة المعتادة هي فيال &quot;قارورة&quot; واحدة (تحتوي على 500 مجم إيميبينيم، و 500 مجم سيلاستاتين، و 250 مجم ريلبَكتام) كل 6 ساعات. إذا كنت تعاني من مشاكل في الكلى، فقد يقوم طبيبك بتخفيض جرعتك.</p><p dir="RTL">يتم إعطاء ريكاربريو عن طريق التنقيط مباشرة في الوريد (&quot;التسريب في الوريد&quot;). سيستمر التسريب لمدة 30 دقيقة.</p><p dir="RTL">تستمر دورة العلاج عادةً من 5 إلى 14 يومًا، تبَعًا لنوع العدوى التي تعاني منها وكيفية استجابتك للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك ريكاربريو أكثر مما ينبغي</strong></p><p dir="RTL">سيتم إعطاؤك ريكاربريو من قبل طبيب أو ممرض، لذلك من غير المحتمل أن يتم إعطاؤك جرعة خاطئة. إذا كنت تعتقد أنك قد تلقيت الكثير من ريكاربريو، أخبر طبيبك أو ممرضك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تتلقى جرعة من ريكاربريو</strong></p><p dir="RTL">أخبر طبيبك أو ممرضتك على الفور إذا كنت تعتقد أنك لم تتلق جرعتك من ريكاربريو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو ممرضك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، على الرغم من أنها لا تحدث لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية خطيرة</strong></p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت أيًا من الأعراض الجانبية الخطيرة التالية &ndash; إذ يجب إيقاف الدواء:</p><p dir="RTL">&bull; ردود الفعل التحسسية - قد تشمل العلامات شرى وتورم في الوجه والشفتين واللسان أو الحلق وصعوبة في التنفس أو البلع</p><p dir="RTL">&bull; ردود فعل جلدية شديدة (على سبيل المثال، طفح جلدي شديد، تقشّر أو ظهور تقرحات)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong></p><p dir="RTL"><strong>الشائعة:</strong> (قد تظهر لدى ما يصل إلى 1 من كل 10 أشخاص).</p><p dir="RTL">&bull; الغثيان، القيء، الإسهال</p><p dir="RTL">&bull; نتائج فحص الدم التي قد تُظهر تغيرات في وظائف الكبد</p><p dir="RTL">&bull; نتائج فحص الدم التي قد تُظهر زيادة في عدد بعض أنواع خلايا الدم المسماة &quot;الحمضات&quot;</p><p dir="RTL">&bull; نتائج فحص الدم التي قد تُظهر زيادة في عدد بعض خلايا الدم البيضاء</p><p dir="RTL">&bull; طفح جلدي</p><p dir="RTL">&bull; التهاب وألم ناتج عن جلطة دموية في الوريد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير الشائعة:</strong> (قد تظهر لدى ما يصل إلى 1 من كل 100 شخص)</p><p dir="RTL">&bull; الشرى</p><p dir="RTL">&bull; حكة بالجلد</p><p dir="RTL">&bull; التشنجات (النوبات) ومشاكل الجهاز العصبي مثل الرعاش</p><p dir="RTL">&bull; ارتباك</p><p dir="RTL">&bull; رؤية أو سماع أو الشعور بشيء غير موجود (هلوسة)</p><p dir="RTL">&bull; دوار، نعاس</p><p dir="RTL">&bull; انخفاض ضغط الدم</p><p dir="RTL">&bull; نتائج فحص الدم التي قد تُظهر تغيرات في وظائف الكلى</p><p dir="RTL">&bull; نتائج فحص الدم التي قد تُظهر انخفاضًا في عدد خلايا الدم الحمراء وخلايا الدم البيضاء وخلايا الدم التي تسمى الصفائح الدموية.</p><p dir="RTL">&bull; نتائج فحص الدم التي قد تُظهر زيادة في عدد بعض خلايا الدم التي تسمى الصفائح الدموية</p><p dir="RTL">&bull; خلل في وظائف الكلى والكبد والدم يظهر عن طريق فحوصات الدم</p><p dir="RTL">&bull; ألم أو احمرار أو تكتّل موضع حقن الدواء</p><p dir="RTL">&bull; حُمّى</p><p dir="RTL">&bull; نتائج فحص الدم (تسمى اختبار كومبس) تُبيّن ظهور الأجسام المضادة التي يمكن أن تسبب فقر الدم عن طريق تدمير خلايا الدم الحمراء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النّادرة:</strong> (قد تظهر لدى ما يصل إلى 1 من كل 1000 شخص)</p><p dir="RTL">&bull; عدوى فطرية (داء المبيضات)</p><p dir="RTL">&bull; تغيرات في حاسّة الذوق</p><p dir="RTL">&bull; اعتلال الدماغ ، إحساس بالوخز (وخز وشكشكة)، ورعاش موضعي</p><p dir="RTL">&bull; فقدان السمع</p><p dir="RTL">&bull; تصبّغ الأسنان و / أو اللسان</p><p dir="RTL">&bull; التهاب القولون مع الإسهال الشديد (التهاب القولون)</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم البيضاء مما قد يجعل من الصعب على جسمك محاربة العدوى</p><p dir="RTL">&bull; التهاب الكبد</p><p dir="RTL">&bull; فشل كبدى</p><p dir="RTL">&bull; عدم قدرة الكلى على أداء وظائفها الطبيعية</p><p dir="RTL">&bull; تغيرات في كمية أو لون البول</p><p dir="RTL">&bull; تورّم الجلد</p><p dir="RTL">&bull; طفح جلدي مؤلم مصحوب بأعراض تشبه أعراض الأنفلونزا</p><p dir="RTL">&bull; احمرار وتقشر الجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النادرة جدًّا:</strong> (قد تظهر لدى ما يصل إلى 1 من بين 10000 شخص)</p><p dir="RTL">&bull; التهاب المعدة أو الأمعاء (التهاب المعدة والأمعاء)</p><p dir="RTL">&bull; فقر الدم الناجم عن تدمير خلايا الدم الحمراء مما يؤدي إلى أعراض مثل التعب وشحوب الجلد</p><p dir="RTL">&bull; صُدَاع</p><p dir="RTL">&bull; تفاقم مرض نادر مرتبط بضعف العضلات (تفاقم الوهن العضلي الشديد)</p><p dir="RTL">&bull; إحساس بالدُّوار</p><p dir="RTL">&bull; رنين في الأذنين (طنين)</p><p dir="RTL">&bull; عدم انتظام ضربات القلب، حيث يبدأ القلب بالنبض بقوة أو بسرعة</p><p dir="RTL">&bull; انزعاج في الصدر، صعوبة في التنفس، تنفس سطحي وسريع بشكل غير طبيعي، ألم في العمود الفقري<br />&nbsp; العلوي</p><p dir="RTL">&bull; ألم في الحلق</p><p dir="RTL">&bull; احمرار الوجه والرقبة، ازرقاق الوجه والشفتين، تغيرات في ملمس الجلد، تعرّق زائد</p><p dir="RTL">&bull; زيادة في إفراز اللعاب</p><p dir="RTL">&bull; التهاب الأمعاء مع الإسهال الدموي (التهاب القولون النزفي)</p><p dir="RTL">&bull; آلام في المعدة</p><p dir="RTL">&bull; حرقة المعدة</p><p dir="RTL">&bull; احمرار وتورّم اللسان، فرط نمو النتوءات الطبيعية على اللسان مما يجعله يبدو مكسوًّ بالشعر</p><p dir="RTL">&bull; تدنّي شديد في وظائف الكبد بسبب الالتهاب (التهاب الكبد الخاطف)</p><p dir="RTL">&bull; ألم في عدة مفاصل</p><p dir="RTL">&bull; حكة في الفرج عند النساء</p><p dir="RTL">&bull; الضعف وقلة الطاقة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير المعروفة:</strong> (لا يمكن تقدير ترددها من البيانات المتاحة)</p><p dir="RTL">&bull; الهيجان</p><p dir="RTL">&bull; حركات غير طبيعية</p><p dir="RTL">&bull; اليرقان (اصفرار الجلد والعينين)</p><p dir="RTL">&bull; اختبارات الدم التي تُظهر ارتفاع في مستوى مادة تسمى نازعة هيدروجين اللاكتات (LDH) والتي قد تكون<br />&nbsp; علامة على تلف الأنسجة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا عانيت من أيّ أعراضٍ جانبيّة، فتحدث إلى طبيبك أو ممرضك. يتضمن ذلك أي أعراض جانبية محتملة غير مُدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً عبر المركز الوطني للتيقظ والسلامة الدوائية ، الهيئة العامة للغذاء والدواء. يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن الأعراض الجانبية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">يُحفظ هذا الدواء بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة.</p><p dir="RTL">احتفظ بهذا الدواء في الكرتون الخارجي لحمايته من الضوء.</p><p>لا تتخلّص من الأدوية عبر مياه الصرف الصحي. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات ريكاربريو</strong></p><p dir="RTL">&bull; المواد الفعالة هي إيميبينيم وسيلاستاتين وريلبَكتام. تحتوي كل قارورة على 500 مجم إيميبينيم و 500 مجم سيلاستاتين و 250 مجم ريلبَكتام.</p><p dir="RTL">&bull; المكون الآخر هو بيكربونات الصوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشكل الصيدلاني لريكاربريو ووصفه وحجم عبوته</strong></p><p dir="RTL">يتوفّر ريكاربريو على شكل مسحوق أبيض أو مائل إلى اللون الأصفر في قوارير (فيال) زجاجية وهو مُعد لتحضير محلول للحقن بالتسريب الوريدي. تحتوي العبوة على 25 فيال &quot;قارورة&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق والشركة الصانعة:</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:633px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الشركة المالكة لحقوق التسويق :</strong></p><p dir="RTL">ميرك شارب و دوم بي. في.</p><p dir="RTL">واردرويج</p><p dir="RTL">٢٠٣١ بي ان هارلم</p><p dir="RTL">هولندا</p></td><td style="vertical-align:top"><p dir="RTL"><strong>الشركة الصانعة </strong></p><p dir="RTL">شركة ميرك شارب ودوم&nbsp;ذ م م</p><p dir="RTL">2778 الطريق السريع الجنوبي الشرقي</p><p dir="RTL">إلكتون، فيرجينيا 22827، الولايات المتحدة الأمريكية</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Recarbrio 500 mg/500 mg/250 mg powder for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains imipenem monohydrate equivalent to 500 mg imipenem, cilastatin sodium equivalent to 500 mg cilastatin, and relebactam monohydrate equivalent to 250 mg relebactam.

Excipient(s) with known effect
The total amount of sodium in each vial is 37.5 mg (1.6 mmol). For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion. A white to light yellow powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Recarbrio is indicated for:</p><p>&bull;&nbsp; Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults (see sections 4.4 and 5.1).</p><p>&bull;&nbsp; Treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults.</p><p>&bull;&nbsp; Treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4, and 5.1).</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>It is recommended that Recarbrio should be used to treat infections due to aerobic Gram-negative organisms in adult patients with limited treatment options only after consultation with a physician with appropriate experience in the management of infectious diseases.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Table 1 shows the recommended intravenous dose for patients with a creatinine clearance (CrCl) &ge; 90 mL/min (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>Table 1: Recommended intravenous dose for patients with a creatinine clearance (CrCl) &ge; 90 mL/min<sup>1,2</sup></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Type of infection</strong></p></td><td style="vertical-align:top"><p><strong>Dose of Recarbrio</strong></p><p><strong>(imipenem/cilastatin/ relebactam)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Infusion time</strong></p></td><td style="vertical-align:top"><p><strong>Duration of treatment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hospital-acquired pneumonia, including ventilator associated</p><p>pneumonia<sup>2,3</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>500 mg/500 mg/250 mg</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Every 6 hours</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>30 mins</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Infections due to aerobic Gram-negative organisms in patients with limited</p><p>treatment options<sup>2</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>500 mg/500 mg/250 mg</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Every 6 hours</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>30 mins</p></td><td style="vertical-align:top"><p>Duration in accordance with the site of</p><p>infection<sup>4</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>1</sup>As calculated using the Cockcroft-Gault formula.</p><p><sup>2</sup>For HAP or VAP patients with CrCl ˃ 250 mL/min, and for patients with complicated intra-abdominal infections (cIAI) or complicated urinary tract infections (cUTI), including pyelonephritis with</p><p>CrCl ˃ 150 mL/min, the recommended dose of Recarbrio may not be sufficient (see section 4.4).</p><p><sup>3</sup>Includes bacteraemia, in association with, or suspected to be associated with, HAP or VAP.</p><p><sup>4</sup>e.g., for cIAI and cUTI the recommended treatment duration is 5 to 10 days; treatment may continue up to 14 days.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Patients who have a CrCl less than 90 mL/min require dosage reduction of Recarbrio as indicated in Table 2. For patients with fluctuating renal function, CrCl should be monitored.</p><p>&nbsp;</p><p>Table 2: Recommended intravenous doses for patients with a CrCl &lt; 90 mL/min</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Estimated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Creatinine&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clearance (mL/min)<sup>*</sup></strong></p></td><td style="vertical-align:top"><p><strong>Recommended dosage of Recarbrio (imipenem/cilastatin/relebactam) (mg)</strong><sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Less than 90 to greater than or equal to 60</p></td><td style="vertical-align:top"><p>400/400/200</p></td></tr><tr><td style="vertical-align:top"><p>Less than 60 to greater than or equal to 30</p></td><td style="vertical-align:top"><p>300/300/150</p></td></tr><tr><td style="vertical-align:top"><p>Less than 30 to greater than or equal to 15</p></td><td style="vertical-align:top"><p>200/200/100</p></td></tr><tr><td style="vertical-align:top"><p>End&nbsp;&nbsp;&nbsp;&nbsp; stage&nbsp;&nbsp;&nbsp;&nbsp; renal&nbsp;&nbsp;&nbsp;&nbsp; disease&nbsp;&nbsp;&nbsp;&nbsp; (ESRD)&nbsp;&nbsp;&nbsp;&nbsp; on</p><p>haemodialysis<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>200/200/100</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>*</sup>CrCl calculated using the Cockcroft-Gault formula.</p><p><sup>&dagger;</sup>Administer intravenously over 30 minutes every 6 hours.</p><p><sup>&Dagger;</sup>Administration should be timed to follow haemodialysis. Imipenem, cilastatin, and relebactam are cleared from the circulation during haemodialysis.</p><p>Recarbrio is provided as a single vial in a fixed-dose combination; the dose for each component will</p><p>be adjusted equally during preparation (see section 6.6).</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Patients with CrCl less than 15 mL/min should not receive Recarbrio unless haemodialysis is instituted within 48 hours. There is inadequate information to recommend usage of Recarbrio for patients undergoing peritoneal dialysis.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is required in patients with impaired hepatic function (see section 5.2).</p><p>&nbsp;</p><p><em>Elderly population</em></p><p>No dose adjustment is required for elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of imipenem/cilastatin/relebactam in children and adolescents below 18 years of age have not yet been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Intravenous use.</p><p>&nbsp;</p><p>Recarbrio is administered by intravenous infusion over 30 minutes.</p><p>&nbsp;</p><p>Recarbrio must be reconstituted (see sections 6.2, 6.3, and 6.6) prior to intravenous infusion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. Hypersensitivity to any other carbapenem antibacterial agent.
Severe hypersensitivity (e.g., anaphylactic reaction, severe skin reaction) to any other type of beta- lactam antibacterial agent (e.g., penicillins, cephalosporins or monobactams) (see section 4.4).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity reactions</u></p><p>&nbsp;</p><p>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams (see sections 4.3 and 4.8).</p><p>&nbsp;</p><p>These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. Before initiating therapy with Recarbrio, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta-lactams, and other allergens.</p><p>&nbsp;</p><p>If an allergic reaction to Recarbrio occurs, treatment with Recarbrio must be discontinued immediately. Serious anaphylactic reactions require immediate emergency treatment.</p><p>&nbsp;</p><p><u>Hepatic function</u></p><p>&nbsp;</p><p>Hepatic function should be closely monitored during treatment with Recarbrio due to the risk of hepatic toxicity (such as increase in transaminases, hepatic failure, and fulminant hepatitis) (see section 4.8).</p><p>&nbsp;</p><p>Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with Recarbrio. There is no dose adjustment necessary (see section 4.2).</p><p>&nbsp;</p><p><u>Central nervous system (CNS)</u></p><p>&nbsp;</p><p>CNS adverse reactions, such as seizures, confusional states, and myoclonic activity have been reported during treatment with imipenem/cilastatin, components of Recarbrio, especially when recommended dosages of imipenem were exceeded<em>. </em>These reactions have been reported most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) and/or compromised renal function<em>.</em></p><p><em>&nbsp;</em></p><p><u>Increased seizure potential due to interaction with valproic acid</u></p><p>&nbsp;</p><p>The concomitant use of Recarbrio and valproic acid/divalproex sodium is not recommended. Antibacterials other than carbapenems should be considered to treat infections in patients whose seizures are well-controlled on valproic acid or divalproex sodium. If administration of Recarbrio is necessary, supplemental anti-convulsant therapy should be considered (see section 4.5).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Clostridioides difficile</u></em><u>-Associated Diarrhoea (CDAD)</u></p><p>&nbsp;</p><p><em>Clostridioides difficile</em>-associated diarrhoea (CDAD) has been reported with Recarbrio. CDAD may range in severity from mild diarrhoea to fatal colitis. CDAD must be considered in all patients who present with diarrhoea during or following the administration of Recarbrio (see section 4.8). Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p><p>&nbsp;</p><p>If CDAD is suspected or confirmed, discontinuation of therapy with Recarbrio, and the administration of specific treatment for <em>C. difficile </em>should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p>&nbsp;</p><p><u>Patients with CrCl &ge; 150 mL/min</u></p><p>&nbsp;</p><p>Based on pharmacokinetic-pharmacodynamic analyses, the dose of Recarbrio that is recommended for patients with CrCl of &ge; 90 mL/min may not be sufficient to treat patients with HAP or VAP and CrCl</p><p>&gt; 250 mL/min, or patients with cIAI or cUTI and CrCl &gt; 150 mL/min. Consideration should be given to using alternative therapies for these patients.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>Dose adjustment is recommended in patients with renal impairment (see section 4.2). There is inadequate information to recommend usage of Recarbrio for patients undergoing peritoneal dialysis.</p><p>&nbsp;</p><p><u>Limitations of the clinical data</u></p><p>&nbsp;</p><p>Patients who were immunocompromised, including those with neutropenia, were excluded from clinical trials.</p><p>&nbsp;</p><p><em>Hospital-acquired pneumonia, including ventilator-associated pneumonia</em></p><p>In a single study of hospital-acquired pneumonia, including ventilator-associated pneumonia, 6.2 % (33/535) of patients had bacteraemia at baseline.</p><p>&nbsp;</p><p><em>Patients with limited treatment options</em></p><p>The use of Recarbrio to treat patients with infections due to aerobic Gram-negative organisms who have limited treatment options is based on experience with imipenem/cilastatin, pharmacokinetic- pharmacodynamic analysis for imipenem/cilastatin/relebactam, and on limited data from a randomised clinical study in which 21 evaluable patients were treated with Recarbrio and 10 evaluable patients were treated with colistin and imipenem/cilastatin for infections caused by imipenem-non-susceptible organisms.</p><p>&nbsp;</p><p><u>Limitations of the spectrum of antibacterial activity</u></p><p>&nbsp;</p><p>Imipenem does not have activity against methicillin-resistant <em>Staphylococcus aureus </em>(MRSA) and <em>Staphylococcus epidermidis </em>(MRSE) or against <em>Enterococcus faecium</em>. Alternative or additional antibacterial agents should be used when these pathogens are known or suspected to be contributing to the infectious process.</p><p>&nbsp;</p><p>The inhibitory spectrum of relebactam includes class A beta-lactamases (such as ESBLs and KPC) and Class C beta-lactamases including PDC. Relebactam does not inhibit class D carbapenemases such as OXA-48 or class B metallo-beta-lactamases such as NDM and VIM (see section 5.1).</p><p>&nbsp;</p><p><u>Non-susceptible organisms</u></p><p>&nbsp;</p><p>The use of imipenem/cilastatin/relebactam may result in the overgrowth of non-susceptible organisms, which may require interruption of treatment or other appropriate measures.</p><p>&nbsp;</p><p><u>Antiglobulin test (Coombs test) seroconversion</u></p><p>&nbsp;</p><p>A positive direct or indirect Coombs test may develop during treatment with imipenem/cilastatin/relebactam (see section 4.8).</p><p>&nbsp;</p><p><u>Controlled sodium diet</u></p><p>&nbsp;</p><p>Each vial contains a total of 37.5 mg of sodium (1.6 mmol), equivalent to 1.9 % of the WHO (World Health Organization) recommended maximum daily intake of 2 g sodium for an adult. This should be considered when administering Recarbrio to patients who are on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Ganciclovir</u></p><p>&nbsp;</p><p>Generalised seizures have been reported in patients who received ganciclovir concomitantly with imipenem/cilastatin, components of Recarbrio. Ganciclovir should not be used concomitantly with Recarbrio unless the potential benefits outweigh the risks.</p><p>&nbsp;</p><p><u>Valproic acid</u></p><p>&nbsp;</p><p>Case reports in the literature have shown that co-administration of carbapenems, including imipenem/cilastatin (components of Recarbrio), to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Although the mechanism of this interaction is unknown, data from <em>in vitro </em>and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid&#39;s glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid<em>. </em>The concomitant use of Recarbrio and valproic acid/divalproex sodium is not recommended (see section 4.4).</p><p>&nbsp;</p><p><u>Oral anti-coagulants</u></p><p>&nbsp;</p><p>Simultaneous administration of antibacterial agents with warfarin may augment its anticoagulant effects. It is recommended that the INR should be monitored as appropriate during and shortly after co-administration of antibiotics with oral anti-coagulant medicinal products.</p><p>&nbsp;</p><p><u>Clinical drug interaction studies</u></p><p>&nbsp;</p><p>A clinical drug-drug interaction study demonstrated that imipenem and relebactam exposures do not increase by a clinically significant extent when Recarbrio is co-administered with the prototypical OAT-inhibitor probenecid, indicating a lack of clinically meaningful OAT-mediated drug-drug interactions. Concomitant administration of imipenem/cilastatin and probenecid increased the plasma level and half-life of cilastatin, though not to a clinically meaningful extent. Therefore, Recarbrio may be administered concomitantly with OAT inhibitors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate and well-controlled studies for the use of imipenem, cilastatin, or relebactam in pregnant women.</p><p>&nbsp;</p><p>Animal studies with imipenem/cilastatin have shown reproductive toxicity in monkeys (see section 5.3). The potential risk for humans is unknown. Animal studies with relebactam do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>Recarbrio should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>&nbsp;</p><p>Imipenem and cilastatin are excreted into the mother&rsquo;s milk in small quantities.</p><p>&nbsp;</p><p>It is unknown whether relebactam is excreted in human milk. Available data in animals have shown excretion of relebactam in the milk of rats (for details see section 5.3).</p><p>&nbsp;</p><p>A risk to breastfed newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue Recarbrio therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no human data available regarding potential effects of imipenem/cilastatin or relebactam treatment on male or female fertility. Animal studies do not indicate harmful effects of imipenem/cilastatin or relebactam on fertility (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Recarbrio has moderate influence on the ability to drive and use machines. CNS adverse reactions, such as seizures, confusional states, and myoclonic activity, have been reported during treatment with imipenem/cilastatin, components of Recarbrio, especially when recommended dosages of imipenem were exceeded (see section 4.4). Therefore, caution should be exercised when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequently occurring adverse reaction (&ge; 2 %) in patients receiving imipenem/cilastatin plus relebactam in pooled Phase 2 trials of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), including pyelonephritis (N = 431) was diarrhoea. The most frequently occurring adverse reactions (&ge; 2 %) in patients receiving Recarbrio in a Phase 3 trial of HAP or VAP (N = 266) were diarrhoea, alanine aminotransferase increased, and aspartate aminotransferase increased.</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>&nbsp;</p><p>The following adverse reactions have been reported during Phase 2 (imipenem/cilastatin plus relebactam including 431 patients) and Phase 3 (Recarbrio including 266 patients) clinical trials and with imipenem/cilastatin in clinical studies or during post-marketing experience with imipenem/cilastatin (see Table 3).</p><p>&nbsp;</p><p>Adverse reactions are classified according to MedDRA System Organ Class and frequency. Frequency categories are derived according to the following conventions: Very common (&ge; 1/10), Common</p><p>(&ge; 1/100 to &lt; 1/10), Uncommon (&ge; 1/1,000 to &lt; 1/100), Rare (&ge; 1/10,000 to &lt; 1/1,000), Very rare (&lt; 1/10,000), and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table 3: Frequency of adverse reactions by system organ class</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Unknown</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pseudomembranous colitis*</p><p><strong>&nbsp;</strong></p><p>Candidiasis*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Gastro- enteritis*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Eosinophilia*</p></td><td style="vertical-align:top"><p>Pancytopenia* Neutropenia* Leukopenia* Thrombocytopenia*</p><p>Thrombocytosis*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Agranulocytosis*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Haemolytic anaemia*</p><p><strong>&nbsp;</strong></p><p>Bone marrow depression*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reactions*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Seizures* Hallucinations* Confusional states* Myoclonic activity* Dizziness*</p><p>Somnolence*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Encephalopathy* Paraesthesia* Focal tremor* Taste perversion*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Aggravatio n of myasthenia gravis*</p><p><strong>&nbsp;</strong></p><p>Headache*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Agitation* Dyskinesia</p><p>*</p></td></tr><tr><td style="vertical-align:top"><p>Ear and</p><p>labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Hearing loss*</p></td><td style="vertical-align:top"><p>Vertigo*</p><p><strong>&nbsp;</strong></p><p>Tinnitus*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cyanosis*</p><p><strong>&nbsp;</strong></p><p>Tachycardi a*</p><p><strong>&nbsp;</strong></p><p>Palpitations</p><p>*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular</p><p>disorders</p></td><td style="vertical-align:top"><p>Thrombophlebiti</p><p>s*</p></td><td style="vertical-align:top"><p>Hypotension*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Flushing*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea*</p><p><strong>&nbsp;</strong></p><p>Hyper- ventilation*</p><p><strong>&nbsp;</strong></p><p>Pharyngeal pain*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Diarrhoea<sup>&dagger;</sup>* Nausea<sup>&dagger;</sup>* Vomiting<sup>&dagger;</sup>*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Staining of teeth and/or tongue*</p></td><td style="vertical-align:top"><p>Haemorrha gic colitis*</p><p><strong>&nbsp;</strong></p><p>Abdominal pain*</p><p><strong>&nbsp;</strong></p><p>Heartburn*</p><p><strong>&nbsp;</strong></p><p>Glossitis*</p><p><strong>&nbsp;</strong></p><p>Tongue papilla hypertroph y*</p><p><strong>&nbsp;</strong></p><p>Increased salivation*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased<sup>&dagger;</sup>*</p><p><strong>&nbsp;</strong></p><p>Aspartate aminotransferase</p><p>increased<sup>&dagger;</sup>*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Hepatic failure* Hepatitis*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Fulminant hepatitis*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Jaundice*</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Rash (e.g., exanthematous)*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Urticaria* Pruritus*</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis*</p><p><strong>&nbsp;</strong></p><p>Angioedema*</p><p><strong>&nbsp;</strong></p><p>Stevens-Johnson syndrome*</p><p><strong>&nbsp;</strong></p><p>Erythema multiforme*</p><p><strong>&nbsp;</strong></p><p>Exfoliative dermatitis*</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Hyperhidro sis*</p><p><strong>&nbsp;</strong></p><p>Skin texture changes*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeleta l and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Polyarthral gia*</p><p><strong>&nbsp;</strong></p><p>Thoracic spine pain*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Elevations in serum creatinine*</p></td><td style="vertical-align:top"><p>Acute renal failure* Oliguria/anuria* Polyuria*</p><p>Urine discoloration (harmless and should not be confused with</p><p>haematuria)*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Pruritus vulvae*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fever*</p><p><strong>&nbsp;</strong></p><p>Local pain and induration at the injection site*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chest discomfort</p><p>*</p><p><strong>&nbsp;</strong></p><p>Asthenia/ weakness*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Investigations</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Increases in serum alkaline phosphatase*</p></td><td style="vertical-align:top"><p>Coombs test positive*</p><p><strong>&nbsp;</strong></p><p>Prolonged prothrombin time*</p><p><strong>&nbsp;</strong></p><p>Decreased haemoglobin*</p><p><strong>&nbsp;</strong></p><p>Increases in serum bilirubin*</p><p><strong>&nbsp;</strong></p><p>Elevations in blood urea nitrogen*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Blood lactate dehydroge nase increased*</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>*reported with imipenem/cilastatin in clinical studies or during post-marketing experience with imipenem/cilastatin</p><p><sup>&dagger;</sup>reported with imipenem/cilastatin plus relebactam in Phase 2 (N = 431) and in Phase 3 (N = 266) studies</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other </u><u>GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, discontinue Recarbrio, treat based on symptoms, and institute general supportive treatment. Imipenem, cilastatin, and relebactam can be removed by haemodialysis. No clinical information is available on the use of haemodialysis to treat overdosage.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, carbapenems, ATC code: J01DH56 <u>Mechanism of action</u></p><p>The bactericidal activity of imipenem results from the inhibition of penicillin binding proteins (PBPs) leading to inhibition of peptidoglycan cell wall synthesis.</p><p>&nbsp;</p><p>Cilastatin limits the renal metabolism of imipenem and does not have antibacterial activity.</p><p>&nbsp;</p><p>Relebactam is a non-beta lactam inhibitor of Ambler class A and class C beta-lactamases, including class A <em>Klebsiella pneumoniae </em>carbapenemase (KPC) and extended-spectrum beta-lactamases (ESBLs), and class C (AmpC-type) beta-lactamases including Pseudomonas-Derived Cephalosporinase (PDC). Relebactam does not inhibit class B enzymes (metallo-beta-lactamases) or class D carbapenemases. Relebactam has no antibacterial activity.</p><p>&nbsp;</p><p><u>Resistance</u></p><p>&nbsp;</p><p>Mechanisms of resistance in Gram-negative bacteria that are known to affect imipenem/relebactam include the production of metallo-beta-lactamases or oxacillinases with carbapenemase activity.</p><p>&nbsp;</p><p>Expression of certain alleles of the class A beta-lactamase Guiana extended-spectrum beta-lactamase (GES) and overexpression of PDC coupled with loss of imipenem entry porin OprD may confer resistance to imipenem/relebactam in <em>P. aeruginosa</em>. The expression of efflux pumps in <em>P. aeruginosa</em></p><p>does not affect activity of either imipenem or relebactam. Mechanisms of bacterial resistance that could decrease the antibacterial activity of imipenem/relebactam in Enterobacterales include porin mutations affecting outer membrane permeability.</p><p>&nbsp;</p><p><u>Antibacterial activity in combination with other antibacterial agents</u></p><p>&nbsp;</p><p><em>In vitro </em>studies have demonstrated no antagonism between imipenem/relebactam and amikacin, azithromycin, aztreonam, colistin, gentamicin, levofloxacin, linezolid, tigecycline, tobramycin, or vancomycin.</p><p>&nbsp;</p><p><u>Susceptibility testing breakpoints</u></p><p>&nbsp;</p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Organism group</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Minimum Inhibitory Concentrations (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Susceptible &le;</strong></p></td><td style="vertical-align:top"><p><strong>Resistant &gt;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Enterobacterales (except</p><p>Morganellaceae)</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas aeruginosa</em></p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter </em>spp.</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Viridans group streptococci</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Anaerobes, Gram-positive</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Anaerobes, Gram-negative</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>&nbsp;</p><p>Time that unbound plasma concentrations of imipenem exceed the imipenem/relebactam minimum inhibitory concentration (% <em>f</em>T &gt; MIC) has been shown to best correlate with efficacy. The ratio of the 24 - hour unbound plasma relebactam AUC to imipenem/relebactam MIC (<em>f</em>AUC / MIC) has been determined to be the index that best predicts activity of relebactam.</p><p>&nbsp;</p><p><u>Clinical efficacy against specific pathogens</u></p><p>&nbsp;</p><p>Efficacy has been demonstrated in clinical studies against the pathogens listed under each indication that were susceptible to imipenem and relebactam <em>in vitro</em>:</p><p>&nbsp;</p><p>Hospital-acquired pneumonia, including ventilator-associated pneumonia</p><p><u>Gram-negative micro-organisms</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Escherichia coli</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Haemophilus influenzae</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Klebsiella pneumoniae</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pseudomonas aeruginosa</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Serratia marcescens</em></p><p><em>&nbsp;</em></p><p><em>In vitro </em>studies suggest that the following pathogens would be susceptible to imipenem and relebactam in the absence of acquired mechanisms of resistance:</p><p>&nbsp;</p><p><u>Gram-negative aerobic micro-organisms</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Acinetobacter calcoaceticus-baumannii </em>complex</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Citrobacter </em>spp. (including <em>C. freundii </em>and <em>C. koseri</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Enterobacter </em>spp. (including <em>E. asburiae </em>and <em>E. cloacae)</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Escherichia coli</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Klebsiella </em>spp. (including <em>K. aerogenes, K. oxytoca </em>and <em>K. pneumoniae</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pseudomonas aeruginosa</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Serratia marcescens</em></p><p><u>Gram-negative anaerobic micro-organisms</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Bacteroides </em>spp. (including <em>B. fragilis</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Fusobacterium </em>spp. (including <em>F. nucleatum </em>and <em>F. necrophorum</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Prevotella </em>spp. (including <em>P. melaninogenica, P. bivia, </em>and <em>P. buccae</em>)</p><p>&nbsp;</p><p><u>Gram-positive aerobic micro-organisms</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Enterococcus faecalis</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Staphylococcus aureus </em>(methicillin susceptible isolates only)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Viridans group streptococci (including <em>S. anginosus </em>and <em>S. constellatus)</em></p><p><em>In vitro </em>studies indicate that the following species are not susceptible to imipenem and relebactam: <u>Gram-negative aerobic micro-organisms</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Legionella </em>spp.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Stenotrophomonas maltophilia</em></p><p><em>&nbsp;</em></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Recarbrio in one or more subsets of the paediatric population in the treatment of Gram-negative bacterial infections (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General introduction</u></p><p>&nbsp;</p><p>The steady-state pharmacokinetic parameters of imipenem, cilastatin, and relebactam in healthy adults with normal renal function (CrCl 90 mL/min or greater), after multiple 30-minute intravenous infusions of 500 mg imipenem/500 mg cilastatin + 250 mg relebactam administered every 6 hours are summarised in Table 4. The steady-state pharmacokinetic parameters of imipenem and relebactam in patients with cIAI or cUTI and HAP or VAP with normal renal function (90 mL/min</p><p>&le; CrCl &lt; 150 mL/min) after multiple 30-minute intravenous infusions of 500 mg imipenem/500 mg cilastatin + 250 mg relebactam administered every 6 hours are summarised in Tables 5 and 6, respectively. Pharmacokinetic parameters were similar for single- and multiple-dose administration due to minimal accumulation.</p><p>&nbsp;</p><p>The C <sub>max</sub> and AUC of imipenem, cilastatin, and relebactam increase in proportion to dose. The elimination half-lives (t <sub>&frac12;</sub>) of imipenem, cilastatin, and relebactam are independent of dose.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 4: Steady-state geometric mean (% geometric co-efficient of variation) plasma pharmacokinetic parameters of imipenem, cilastatin, and relebactam after multiple intravenous 30-minute infusions of 500 mg imipenem/500 mg cilastatin + 250 mg relebactam every 6 hours in healthy adults</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Imipenem (n=6)</strong></p></td><td style="vertical-align:top"><p><strong>Cilastatin (n=6)</strong></p></td><td style="vertical-align:top"><p><strong>Relebactam (n=6)</strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC <sub>0&ndash;</sub> <sub>6</sub> <sub>hr</sub> (&mu;M-hr)</p></td><td style="vertical-align:top"><p>138.0 (17.8)</p></td><td style="vertical-align:top"><p>98.0 (17.0)</p></td><td style="vertical-align:top"><p>81.6 (17.8)</p></td></tr><tr><td style="vertical-align:top"><p>C <sub>max</sub> (&mu;M)</p></td><td style="vertical-align:top"><p>106.0 (26.8)</p></td><td style="vertical-align:top"><p>96.4 (21.8)</p></td><td style="vertical-align:top"><p>48.3 (24.9)</p></td></tr><tr><td style="vertical-align:top"><p>CL (L/hr)</p></td><td style="vertical-align:top"><p>12.0 (17.8)</p></td><td style="vertical-align:top"><p>14.2 (17.0)</p></td><td style="vertical-align:top"><p>8.8 (17.8)</p></td></tr><tr><td style="vertical-align:top"><p>t <sub>1/2</sub> (hr)*</p></td><td style="vertical-align:top"><p>1.1 (&plusmn;0.1)</p></td><td style="vertical-align:top"><p>1.0 (&plusmn;0.1)</p></td><td style="vertical-align:top"><p>1.7 (&plusmn;0.2)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*Arithmetic mean (standard deviation) reported for t <sub>1/2</sub></p><p>AUC <sub>0&ndash;</sub> <sub>6</sub> <sub>hr</sub> = area under the concentration time curve from 0 to 6 hours; C <sub>max</sub> = maximum concentration; CL = plasma clearance; t <sub>1/2</sub>= elimination half-life</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table 5: Population pharmacokinetic model based steady-state geometric mean (% geometric co-efficient of variation) plasma pharmacokinetic parameters of imipenem and relebactam after multiple intravenous 30-minute infusions of Recarbrio (500 mg imipenem/500 mg</strong></p><p>cilastatin/250 mg relebactam) every 6 hours in cIAI or cUTI patients with CrCl 90 mL/min or greater</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Imipenem</strong></p></td><td style="vertical-align:top"><p><strong>Relebactam</strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC <sub>0&ndash;</sub> <sub>24</sub> <sub>hr</sub> (&micro;M-hr)</p></td><td style="vertical-align:top"><p>500.0 (56.3)</p></td><td style="vertical-align:top"><p>390.5 (44.5)</p></td></tr><tr><td style="vertical-align:top"><p>C <sub>max</sub> (&micro;M)</p></td><td style="vertical-align:top"><p>88.9 (62.1)</p></td><td style="vertical-align:top"><p>58.5 (44.9)</p></td></tr><tr><td style="vertical-align:top"><p>CL (L/hr)</p></td><td style="vertical-align:top"><p>13.4 (56.3)</p></td><td style="vertical-align:top"><p>7.4 (44.5)</p></td></tr><tr><td style="vertical-align:top"><p>t <sub>1/2</sub> (hr)*</p></td><td style="vertical-align:top"><p>1.0 (&plusmn;0.5)</p></td><td style="vertical-align:top"><p>1.2 (&plusmn;0.7)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Arithmetic mean (standard deviation) reported for t <sub>1/2</sub></p><p>AUC <sub>0&ndash;</sub> <sub>24</sub> <sub>hr</sub> = area under the concentration time curve from 0 to 24 hours; C <sub>max</sub> = maximum concentration; CL = plasma clearance; t <sub>1/2</sub> = elimination half-life</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 6: Population pharmacokinetic model based steady-state geometric mean (% geometric co-efficient of variation) plasma pharmacokinetic parameters of imipenem and relebactam after multiple intravenous 30-minute infusions of Recarbrio (500 mg imipenem/500 mg cilastatin + 250 mg relebactam) every 6 hours in HAP or VAP patients with CrCl 90 mL/min or greater</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Imipenem</strong></p></td><td style="vertical-align:top"><p><strong>Relebactam</strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0</sub> <sub>-</sub> <sub>24hr</sub> (&micro;M-hr)</p></td><td style="vertical-align:top"><p>812.2 (59.4)</p></td><td style="vertical-align:top"><p>655.2 (47.9)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (&micro;M)</p></td><td style="vertical-align:top"><p>159.1 (62.3)</p></td><td style="vertical-align:top"><p>87.6 (43.8)</p></td></tr><tr><td style="vertical-align:top"><p>CL (L/hr)</p></td><td style="vertical-align:top"><p>8.2 (59.4)</p></td><td style="vertical-align:top"><p>4.4 (47.9)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>AUC<sub>0</sub> <sub>-</sub> <sub>24hr</sub>=area under the concentration time curve from 0 to 24 hours; C<sub>max</sub>=maximum</p><p>concentration; CL=plasma clearance</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Distribution</u></p><p>&nbsp;</p><p>The binding of imipenem and cilastatin to human plasma proteins is approximately 20 % and 40 %, respectively. The binding of relebactam to human plasma proteins is approximately 22 % and is independent of concentration.</p><p>&nbsp;</p><p>The steady-state volume of distribution of imipenem, cilastatin, and relebactam is 24.3 L, 13.8 L, and</p><p>19.0 L, respectively, in subjects following multiple doses infused over 30 minutes every 6 hours.</p><p>&nbsp;</p><p>The penetration into pulmonary epithelial lining fluid (ELF) expressed as the total ELF-to-unbound plasma exposure ratio was 55 % and 54 % for imipenem and relebactam, respectively.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Imipenem, when administered alone, is metabolised in the kidneys by dehydropeptidase-I, resulting in low levels of imipenem (average of 15-20 % of the dose) recovered in human urine. Cilastatin, an inhibitor of this enzyme, effectively prevents renal metabolism so that when imipenem and cilastatin are given concomitantly, adequate levels of imipenem (approximately 70 % of the dose) are achieved in the urine to enable antibacterial activity.</p><p>&nbsp;</p><p>Cilastatin is mainly eliminated in the urine as unchanged parent drug (approximately 70 - 80 % of the dose), with 10 % of the dose recovered as an N-acetyl metabolite, which has inhibitory activity against dehydropeptidase-I comparable to the parent medicinal product.</p><p>&nbsp;</p><p>Relebactam is cleared primarily via renal excretion as unchanged parent drug (greater than 90 % of the dose) and is minimally metabolised. Unchanged relebactam was the only drug-related component detected in human plasma.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Imipenem, cilastatin, and relebactam are mainly excreted by the kidneys.</p><p>&nbsp;</p><p>Following multiple-dose administration of 500 mg imipenem, 500 mg cilastatin, and 250 mg relebactam to healthy male subjects, approximately 63 % of the administered imipenem dose, and 77 % of the administered cilastatin dose are recovered as unchanged parent in the urine. The renal excretion of imipenem and cilastatin involves both glomerular filtration and active tubular secretion. Greater than 90 % of the administered relebactam dose was excreted unchanged in human urine. The mean renal clearance for relebactam is 135 mL/min, close to the plasma clearance (148 mL/min),</p><p>indicating nearly complete elimination of relebactam by the renal route. The unbound renal clearance of relebactam is greater than the glomerular filtration rate, suggesting that in addition to glomerular filtration, active tubular secretion is involved in the renal elimination, accounting for ~ 30 % of the total clearance.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>The pharmacokinetics of relebactam are linear across the 25 mg to 1150 mg dose range studied for a single intravenous administration, and 50 mg to 625 mg dose range studied for multiple intravenous administration every 6 hours up to 7 days. Minimal accumulation of imipenem, cilastatin or relebactam was observed following multiple 30-minute intravenous infusions of relebactam (50 to 625 mg) co-administered with 500 mg imipenem/500 mg cilastatin every 6 hours up to 7 days in healthy adult males with normal renal function.</p><p>&nbsp;</p><p><u>Drug metabolizing enzymes</u></p><p>&nbsp;</p><p>Studies evaluating the potential for imipenem or cilastatin to interact with CYP450 enzymes have not been conducted.</p><p>&nbsp;</p><p>Relebactam at clinically relevant concentrations does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 <em>in vitro </em>in human liver microsomes. Relebactam showed no potential for <em>in vitro </em>induction of CYP1A2, CYP2B6, and CYP3A4 in human hepatocytes. Thus, relebactam is unlikely to cause clinical drug-drug interactions via CYP-mediated pathways.</p><p>&nbsp;</p><p>Imipenem, cilastatin, and relebactam are all cleared primarily via renal excretion unchanged, with metabolism as a minor elimination route. Thus, Recarbrio is unlikely to be subject to drug-drug interactions when co-administered with CYP inhibitors or inducers.</p><p>&nbsp;</p><p><u>Membrane transporters</u></p><p>&nbsp;</p><p>Relebactam does not inhibit the following hepatic and renal transporters <em>in vitro </em>at clinically relevant concentrations: OATP1B1, OATP1B3, OAT1, OAT3, OCT2, P-gp, BCRP, MATE1, MATE2K, or BSEP.</p><p>&nbsp;</p><p>Relebactam is actively secreted into the urine. It is not a substrate of OAT1, OCT2, P-gp, BCRP, MRP2, or MRP4 transporters, but is a substrate of OAT3, OAT4, MATE1 and MATE2K transporters. The active tubular secretion accounts for only approximately 30 % of the total clearance of relebactam, thus, the extent of drug-drug interaction due to inhibition of the tubular transporters is expected to be of minimal clinical significance, which was confirmed with a clinical drug-drug interaction study with probenecid and Recarbrio (see section 4.5).</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p><em>&nbsp;</em></p><p>In a clinical pharmacokinetic study and population pharmacokinetic analysis, clinically relevant differences in exposure (AUC) were observed for imipenem, cilastatin, and relebactam based on the</p><p>&nbsp;</p><p>extent of renal impairment.</p><p>&nbsp;</p><p>In the clinical study, imipenem geometric mean AUCs were up to 1.4 - fold, 1.5 - fold, and 2.5 - fold higher in patients with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects with normal renal function. The respective cilastatin geometric mean AUCs were up to</p><p>1.6 - fold, 1.9 - fold, and 5.6 - fold higher. Relebactam geometric mean AUCs were up to 1.6 - fold,</p><p>2.2 - fold, and 4.9 - fold higher in patients with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects with normal renal function. In patients with End Stage Renal Disease (ESRD) on haemodialysis, imipenem, cilastatin, and relebactam are efficiently removed by haemodialysis.</p><p>&nbsp;</p><p>To maintain systemic exposures similar to patients with normal renal function, dose adjustment is recommended for patients with renal impairment. ESRD patients on haemodialysis should receive Recarbrio after haemodialysis session (see section 4.2).</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p><em>&nbsp;</em></p><p>Imipenem, cilastatin, and relebactam are primarily cleared renally; therefore, hepatic impairment is not likely to have any effect on Recarbrio exposures (see section 4.2).</p><p>&nbsp;</p><p><em><u>Elderly/gender</u></em></p><p><em>&nbsp;</em></p><p>In a geriatric/gender study and population pharmacokinetic analysis no clinically relevant differences in exposure (AUC) were observed for imipenem, cilastatin, and relebactam based on age or gender, apart from the effect of renal function (see section 4.2).</p><p>&nbsp;</p><p><em><u>Race</u></em></p><p><em>&nbsp;</em></p><p>Only a limited number of non-white patients were included in the clinical studies, but no major effect of race on imipenem, cilastatin, and relebactam pharmacokinetics is expected.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Imipenem/cilastatin</u></p><p>&nbsp;</p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, and genotoxicity studies.</p><p>Animal studies showed that the toxicity produced by imipenem, as a single entity, was limited to the kidney. Co-administration of cilastatin with imipenem in a 1:1 ratio prevented the nephrotoxic effects of imipenem in rabbits and monkeys. Available evidence suggests that cilastatin prevents the nephrotoxicity by preventing entry of imipenem into the tubular cells.</p><p>&nbsp;</p><p>A teratology study in pregnant cynomolgus monkeys given imipenem/cilastatin sodium at doses of 40/40 mg/kg/day (bolus intravenous injection) resulted in maternal toxicity including emesis, inappetence, body weight loss, diarrhoea, abortion, and death in some cases. When doses of imipenem/cilastatin sodium (approximately 100/100 mg/kg/day or approximately 3 times the recommended daily human intravenous dose) were administered to pregnant cynomolgus monkeys at an intravenous infusion rate which mimics human clinical use, there was minimal maternal intolerance (occasional emesis), no maternal deaths, no evidence of teratogenicity, but an increase in embryonic loss relative to control groups (see section 4.6).</p><p>&nbsp;</p><p>Long term studies in animals have not been performed to evaluate carcinogenic potential of imipenem/cilastatin.</p><p>&nbsp;</p><p><u>Relebactam</u></p><p>&nbsp;</p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, reproduction toxicity, or genotoxicity. Carcinogenicity studies have not been conducted with relebactam.</p><p>&nbsp;</p><p>Relebactam administered intravenously to lactating rats at a dose of 450 mg/kg/day (GD 6 to LD 14), was excreted into the milk with concentration of approximately 5 % that of maternal plasma concentrations.</p><p>&nbsp;</p><p>Animal studies show that relebactam given as a single entity caused renal tubular degeneration in monkeys at AUC exposure 7-fold the human AUC exposure at the maximum recommended human dose (MRHD). Renal tubular degeneration was shown to be reversible after dose discontinuation. There was no evidence of nephrotoxicity at AUC exposures less than or equal to 3-fold the human AUC exposure at the MRHD.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium hydrogen carbonate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dry powder

36 months.

After constitution and dilution

Diluted solutions should be used immediately. The time interval between the beginning of reconstitution and the end of intravenous infusion should not exceed two hours.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30˚C</p><p>Keep vials in the outer carton in order to protect from light.</p><p>For storage conditions after constitution and dilution of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20 mL glass vial, with 20 mm rubber stopper and aluminium crimp cap seal. This medicinal product is supplied in packs of 25 vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Recarbrio is supplied as a dry powder in a single-dose vial that must be constituted and further diluted using aseptic technique prior to intravenous infusion as outlined below:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To prepare the infusion solution, contents of the vial must be transferred to 100 mL of an appropriate infusion solution (see sections 6.2 and 6.3): 9 mg/mL (0.9 %) sodium chloride. In exceptional circumstances where 9 mg/mL (0.9 %) sodium chloride cannot be used for clinical reasons 5 % glucose may be used instead.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw 20 mL (10 mL times 2) of diluent from the appropriate infusion bag and constitute the vial with 10 mL of the diluent. The constituted suspension must not be administered by direct intravenous infusion.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After constitution, shake vial well and transfer resulting suspension into the remaining 80 mL of the infusion bag.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add the additional 10 mL of infusion diluent to the vial and shake well to ensure complete transfer of vial contents; repeat transfer of the resulting suspension to the infusion solution before administering. Agitate the resulting mixture until clear.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constituted solutions of Recarbrio range from colorless to yellow. Variations of color within this range do not affect the potency of the product.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients with renal insufficiency, a reduced dose of Recarbrio will be administered according to the patient&#39;s CrCl, as determined from Table 7. Prepare 100 mL of infusion solution as directed above. Select the volume (mL) of the final infusion solution needed for the appropriate dose of Recarbrio as shown in Table 7.</p><p>&nbsp;</p><p>Parenteral medicinal products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if discoloration or visible particles are observed.</p><p>&nbsp;</p><p>Table 7: Preparation of Recarbrio doses</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine Clearance (mL/min)</strong></p></td><td style="vertical-align:top"><p><strong>Dosage of Recarbrio </strong><strong>(imipenem/cilastatin/relebactam) (mg)</strong></p></td><td style="vertical-align:top"><p><strong>Volume (mL) of Solution to be Removed and Discarded from</strong></p><p><strong>Preparation</strong></p></td><td style="vertical-align:top"><p><strong>Volume (mL) of Final Infusion Solution Needed for</strong></p><p><strong>Dosage</strong></p></td></tr><tr><td style="vertical-align:top"><p>Greater than</p><p>or equal to 90</p></td><td style="vertical-align:top"><p>500/500/250</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>Less than 90 to greater than</p><p>or equal to 60</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>400/400/200</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>20</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>80</p></td></tr><tr><td style="vertical-align:top"><p>Less than 60</p><p>to greater than or equal to 30</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>300/300/150</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>40</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>60</p></td></tr><tr><td style="vertical-align:top"><p>Less than 30 to greater than or equal to 15 or ESRD on</p><p>haemodialysis</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>200/200/100</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>60</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>40</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><u>Compatible medicinal products</u></p><p>&nbsp;</p><p>The physical compatibility of Recarbrio with selected injectable medicinal products was evaluated in two commonly available diluents at a Y-infusion site. Compatible medicinal products with the corresponding compatible diluent (i.e., 5 % Dextrose Injection or 0.9 % Sodium chloride Injection) are listed below. Recarbrio should not be co-administered through the same intravenous line (or cannula), with other medicinal products not listed below, as no compatibility data are available. Refer to the respective prescribing information of the co-administered medicinal product(s) to confirm</p><p>&nbsp;</p><p>compatibility of simultaneous co-administration. This medicinal product must not be mixed with other medicinal products except those mentioned below.</p><p>&nbsp;</p><p><em>List of Compatible Injectable Medicinal Products for use with 5 % Dextrose or 0.9 % Sodium chloride Injection as Diluents</em></p><p>&bull;&nbsp;&nbsp;&nbsp; dexmedetomidine</p><p>&bull;&nbsp;&nbsp;&nbsp; dopamine</p><p>&bull;&nbsp;&nbsp;&nbsp; epinephrine</p><p>&bull;&nbsp;&nbsp;&nbsp; fentanyl</p><p>&bull;&nbsp;&nbsp;&nbsp; heparin</p><p>&bull;&nbsp;&nbsp;&nbsp; midazolam</p><p>&bull;&nbsp;&nbsp;&nbsp; norepinephrine</p><p>&bull;&nbsp;&nbsp;&nbsp; phenylephrine</p><p>&nbsp;</p><p><u>Compatible intravenous bags and infusion set materials</u></p><p>&nbsp;</p><p>Recarbrio is compatible with the following intravenous container bags and infusion set materials. Any intravenous bags or infusion set materials not listed below should not be used.</p><p>&nbsp;</p><p><em>Intravenous Container Bag Materials</em></p><p>Polyvinyl chloride (PVC) and polyolefin (polypropylene and polyethylene)</p><p>&nbsp;</p><p><em>Intravenous Infusion Set Materials (with tubing)</em></p><p>PVC + Di-(2-ethylhexyl)phthalate (DEHP) and polyethylene (PE)-lined PVC <u>Incompatible medicinal products</u></p><p>Recarbrio for solution for infusion is physically incompatible with propofol in 5 % Dextrose (also named Glucose) or 0.9 % Sodium chloride.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Marketing Authorization Holder:
Merck Sharp & Dohme B.V. Waarderweg 39
2031 BN Haarlem The Netherlands

Manufacturer:
Merck Sharp & Dohme LLC
2778 South East Side Highway
Elkton, Virginia 22827, USA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>